BlossomHill CFO reports option on 175K shares

BlossomHill Therapeutics, Inc. (BLSM) reported the initial insider holdings of its Chief Financial Officer, Jason A. Keyes, on a Form 3.

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) reported the initial insider holdings of its Chief Financial Officer, Jason A. Keyes, on a Form 3. He holds an employee stock option covering 175,417 shares of common stock at an exercise price of $6.28 per share, expiring on May 5, 2035. The option is noted as immediately exercisable and is held as a direct ownership position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Keyes Jason A

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 175,417 contracts (Direct)

Footnotes (1)

1. F1. Immediately Exercisable.

Key Figures

Underlying shares: 175,417 shares of Common Stock Exercise price: $6.28 per share Expiration date: May 5, 2035

3 metrics

Underlying shares 175,417 shares of Common Stock Covered by employee stock option held by CFO Jason A. Keyes

Exercise price $6.28 per share Employee Stock Option (Right to Buy) on BlossomHill Therapeutics common stock

Expiration date May 5, 2035 Expiration of the employee stock option reported as directly owned

Key Terms

Employee Stock Option (Right to Buy), underlying security, immediately exercisable

3 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

underlying security financial

"underlying_security_title: Common Stock"

immediately exercisable financial

"Footnote F1 states: "Immediately Exercisable.""

FAQ

What insider position did BLSM's CFO report on this Form 3?

BlossomHill Therapeutics’ CFO, Jason A. Keyes, reported holding an employee stock option over 175,417 shares of common stock, directly owned, as his initial beneficial ownership disclosure.

What is the exercise price of the CFO’s stock option in BLSM?

The reported employee stock option held by BLSM’s CFO has an exercise price of $6.28 per share for the underlying common stock.

When does the CFO’s reported stock option in BLSM expire?

The employee stock option reported by BLSM’s CFO expires on May 5, 2035, providing a long-dated incentive tied to the company’s common stock.

How many BLSM shares underlie the CFO’s reported option grant?

The employee stock option reported on this Form 3 covers 175,417 underlying shares of BlossomHill Therapeutics, Inc. common stock.

Is the BLSM CFO’s reported stock option currently exercisable?

Yes. A footnote states the employee stock option is immediately exercisable, meaning the CFO can convert the option into common shares at the stated exercise price, subject to any applicable company or regulatory constraints not described here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 03:04 PM Accepted by SEC EDGAR 08/06/2026 - 08:35 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Keyes Jason A

(Last) (First) (Middle)

C/O BLOSSOMHILL THERAPEUTICS, INC.

10255 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121-1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
BlossomHill Therapeutics, Inc. [ BLSM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	05/05/2035	Common Stock	175,417	$6.28	D

Explanation of Responses:

1. Immediately Exercisable.

	/s/ Vincent Liptak, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)